Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study

Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study

Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach t...

Full description

Bibliographic Details
Main Authors: Valentina Zuccaro, Greta Petazzoni, Irene Mileto, Marta Corbella, Erika Asperges, Paolo Sacchi, Sara Rattotti, Marzia Varettoni, Irene Defrancesco, Patrizia Cambieri, Fausto Baldanti, Luca Arcaini, Raffaele Bruno
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Microorganisms
Subjects:
gut microbiota
B cell receptor inhibitors
chronic lymphocytic leukemia
clinical response
Online Access:https://www.mdpi.com/2076-2607/11/5/1305

Internet

https://www.mdpi.com/2076-2607/11/5/1305

Similar Items